Video

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

Author(s):

Joyce A. O'Shaughnessy, MDSara M. Tolaney, MD, MPH

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

Data from the following clinical trial are discussed:

  • LBA17_PR - Overall survival (OS) results from the phase 3 MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Related Videos
VK Gadi, MD, PhD
Ana Christina Garrido-Castro, MD
Julia Foldi, MD, PhD
Kevin Kalinsky, MD, MS
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Related Content
Lydia Pace, MD, MPH
June 5th 2024

A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Giuseppe Curigliano, MD, PhD
June 2nd 2024

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Kevin Kalinsky, MD, MS, of Winship Cancer Institute
June 2nd 2024

Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

Dejan Juric, MD
June 1st 2024

Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer